Tambe takes over from the outgoing Dr Arun Chandavarkar, who will continue to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics

Shreehas Tambe, Deputy CEO of Biocon Biologics, has been appointed as the Managing Director and CEO of the Company from December 5, 2022. Tambe will lead BBL in realising its goal of being a global biosimilars leader, the global biopharmaceutical company said in a statement on Monday. 

Tambe takes over from the outgoing Dr Arun Chandavarkar, who will continue to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics.

Commenting on the appointment, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said, “I am extremely pleased that Shreehas is taking on the responsibility of leading Biocon Biologics as MD and CEO at a time when the company is gearing up for global leadership in biosimilars with the closing of the Viatris acquisition. His demonstrated track record of business success, deep technical and operational expertise provide him with proven leadership capabilities to assume this role."

Shreehas Tambe, Managing Director and CEO, Biocon Biologics, said, “As I step into the role of Managing Director and CEO, I am deeply humbled and honored by the confidence that the Board of Biocon Biologics has reposed in me to lead the company. It has been an absolute privilege to have participated in the evolution of Biocon from an enzymes company to a global biopharmaceutical enterprise. The recent acquisition of Viatris’ global biosimilars business, is a game-changing event in our journey. I am looking forward to leading Biocon Biologics in the next phase of growth.”

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build and shape Biocon’s biosimilars business and spearheaded the Group’s strategic capital investments, including its first overseas facility in Malaysia. He has also been instrumental in securing regulatory approvals and enabling the successful launch of several of the Company’s biosimilar assets in global markets such as the U.S. and EU.

Tambe holds a Masters’ degree in Bioprocess Technology from ICT (UDCT), University of Mumbai and has also studied Pharmaceutical Sciences & Technology at the University of Pune. He was conferred the coveted Distinguished Alumnus Award (Professional) by his alma mater, the prestigious ICT, Mumbai, in 2020